alt=

KYPHA

Kypha seeks to discover, develop and commercialize innovative in-vitro diagnostic biomarker tests within the inflammation and autoimmune space. Our plan is for these tests to become standard of care, having application across a wide range of indications.

Learn More

SCIENCE

There are many ways that the human body can be harmed, physical injury such as head trauma during a sport, or illness like a bacterial infection. The body’s immune system’s response is similar to both, initiating beneficial inflammation.

Learn More

About us

Kypha seeks to discover, develop and commercialize innovative in-vitro diagnostic biomarker tests within the inflammation and autoimmune space. Our plan is for these tests to become standard of care, having application across a wide range of indications that include: lupus, stroke, traumatic brain injury, preeclampsia, infection, kidney disease, and transplant rejection. Potential implications include earlier prediction of adverse events, optimizing treatment options, and overall better patient disease management.

Chad Stiening, Kypha CEO